{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 175,
  "pageCount": 366,
  "prevPage": 174,
  "nextPage": 176,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "The slide uses a list of adverse events to build a case for cardiotoxicity, highlighting specific fatal and serious outcomes.",
  "elementsJson": [
    "paragraph",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/175",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-175",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.86,
        "x": 0.07,
        "y": 0.48
      },
      "kind": "callout",
      "text": "Serious adverse event reports which contain the following symptoms or combinations of symptoms",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b56592d6-ba10-468c-bca1-2d78a1751119",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "Below we list the large number of serious adverse events which indicate cardiotoxicity – generally requiring hospitalization.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd6-da863ada89d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.42,
        "w": 0.86,
        "x": 0.07,
        "y": 0.52
      },
      "kind": "list",
      "text": "Myocardial infarction/dizziness – fatal (1)\nCardiac arrest (1)\nMyocardial infarction/loss of consciousness/cardiac disorder (1)\nLoss of consciousness (1)\nDizziness/irregular heartbeat/blurry vision (7)\nHypertension/tachycardia (8)\nPalpitations/chest pain (4)\nSeizure/QT prolongation per ECG/delirium (1)\nAbnormal QT interval per ECG (1)\nSeizure (2)\nAtrial fibrillation (1)\nPericarditis (1)\nIschemic stroke (1)\nMyocarditis (1)\nChest pain/vomiting (1)\nTachycardia/palpitations/cardiac disorder (1)\nVertigo/hypertension (1)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96d07dff-b10a-49f0-975b-4d4faf3947eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "serious adverse events: 137",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd6-df07fd2d3014",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.42,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "137 of the 612 cases are classified as serious adverse events of which we note one recent (2022) fatality (dizziness/heart attack two weeks after starting the drug and on the first day the dose was titrated to the max 35.6mg); 2 disabled (17 and 52-year old); 2 life-threatening; and 42 hospitalizations. Below we list the large number of serious adverse events which indicate cardiotoxicity – generally requiring hospitalization. We note that dizziness and seizures are among the most common symptoms of QT prolongation. Across both serious and non-serious event reports, we counted 29 that mentioned “dizziness.” Within serious adverse events specifically, per the list below, we note the frequency of events involving cardiac arrest, myocardial infarction, loss of consciousness, QT prolongation, atrial fibrillation, myocarditis, palpitations, vertigo, hypertension, and stroke.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebdfaa21-db5a-454a-b659-cae8c0e4d87b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.07,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital analysis and estimates based on FDA FAERS database for Wakix; pitolisant; pitolisant hydrochloride",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3edb8324-d023-468e-bd19-bb5671c81a73",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}